(PQC3) Genomic Diversity and Microenvironment as Drivers of Metastasis in DCIS

(PQC3) 基因组多样性和微环境作为 DCIS 转移的驱动因素

• 批准号: 8687308
• 负责人: E.Shelley Hwang
• 金额: $ 48.63万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-01 至 2018-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8687308
• 关键词: Algorithms; Barrett Esophagus; Biological Markers; Cells; Characteristics; Clinical; Clinical Trials; Clonal Expansion; Computational algorithm; Data Set; Development; Diagnosis; Discrimination; Disease; Evaluation; Evolution; Genetic; Genetic Drift; Genetic Processes; Genetic Variation; Genetic screening method; Genomics; Goals; Health; Heterogeneity; Hypoxia; Image Analysis; Immune; Intervention; Learning; Lesion; Lung Adenocarcinoma; Malignant Neoplasms; Measurable; Measures; Metastatic to; Mutation; Natural Selections; Nature; Neoplasm Metastasis; Neoplasms; Noninfiltrating Intraductal Carcinoma; Outcome; Patients; Performance; Population; Premalignant; Process; Process Measure; Prognostic Marker; Recurrence; Sampling; Screening Result; Signal Transduction; Solid Neoplasm; Solutions; Testing; Validation; Weight; base; breast lesion; cancer type; case control; cell motility; design; exome sequencing; malignant breast neoplasm; migration; neoplastic cell; outcome forecast; pressure; prognostic; tool; tumor; tumor microenvironment; tumor progression

DESCRIPTION (provided by applicant): Ductal carcinoma in situ (DCIS) is a preinvasive lesion of the breast that makes up almost 30% of all mammographically detected malignancies [1,2]. In DCIS, as for many pre-malignant lesions, the main clinical challenge is predicting which lesions are likely to progress to invasive and metastatic disease. In the absence of reliable prognostic tools, all DCIS is treated as if it would progress, resulting in harm for those patients whose DCIS lacks potential for progression. Thus accurate and clinically actionable prognostic markers for DCIS are critically needed. Neoplasms progress through a process of random mutations and clonal expansions, leading to widespread heterogeneity both between and within neoplasms [4] that makes it challenging to predict prognosis on the basis of specific markers. Moreover, the clonal diversity within a neoplasm is overlaid upon a background of heterogeneous microenvironments, which can accelerate the evolutionary process [5,6] by imposing different selective pressures on different meta-populations in different tumor regions [7]. Genetic diversity in a population is the fuel for natural selection and is a key determinant of the rate of evolution [8,9]. The more genetic and microenvironmental diversity, the more opportunities for selection to drive clonal expansions and for the neoplasm to adapt to new selective pressures. Our solution to the problem of predicting progression given its stochastic nature is not to measure the products of somatic evolution (e.g., presence/absence of a mutation), but to measure the process of somatic evolution (e.g., genetic diversity).

描述（由申请人提供）：导管原位癌（DCIS）是一种乳腺浸润前病变，占所有乳腺X线检查发现的恶性肿瘤的近30%[1，2]。在DCIS中，与许多癌前病变一样，主要的临床挑战是预测哪些病变可能进展为浸润性和转移性疾病。在缺乏可靠的预后工具的情况下，所有DCIS都被视为会进展，这对DCIS缺乏进展潜力的患者造成了伤害。因此，DCIS的准确和临床可操作的预后标志物是迫切需要的。肿瘤通过随机突变和克隆扩增的过程进展，导致肿瘤之间和肿瘤内的广泛异质性[4]，这使得基于特定标志物预测预后具有挑战性。此外，肿瘤内的克隆多样性覆盖在异质性微环境的背景上，这可以通过对不同肿瘤区域中的不同元群体施加不同的选择压力来加速进化过程[5，6][7]。种群中的遗传多样性是自然选择的燃料，也是进化速度的关键决定因素[8，9]。遗传和微环境的多样性越多，选择驱动克隆扩张的机会就越多，肿瘤适应新的选择压力的机会就越多。鉴于其随机性，我们对预测进展问题的解决方案不是测量体细胞进化的产物（例如，突变的存在/不存在），但是为了测量体细胞进化的过程（例如，遗传多样性）。